sorafenib,gilteritinib,midostaurin
amgen,bayer,Astellas Pharmaceuticals,daiichi sankyo,novartis
['leusm', 'sorafenib']
#eha22 #leusm zeidan: in aggregate the data supporting use of flt3i post-allo are strong. best outcomes on admiral were w hct and gilt maint. data for sorafenib (sormain, strongly favor soraf) and mido (radius; marginally favor mido) lead us while awaiting 1506 gilt data 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)